← Leaderboards
Guy Soo Hoo
University Of California Los Angeles
$344,349
Attributed
$1,526,746
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $390K · FY2017–21$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,526,746 · 2
By mechanism
UH3$1,158,300 · 1
UH2$368,446 · 1
Top collaborators
- David S Chia5 shared
- Fang Wei5 shared
- David T Wong5 shared
- Kingshuk Das2 shared
- Charles Martin Strom1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Johannes Czernin$5,995,082
- Ralf Landgraf$4,127,423
- David T Wong$54,826,713
- Jerome A. Zack$38,514,975
- Judith S. Currier$525,401,794
Others in their field
Other Emerging Leaders on “Cost”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Scott Topper · Broad Institute, Inc.$77,958,806
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Mark Marino · Venturewell$48,913,644
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,367,817
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
Research focus
CostDecision MakingAccreditationAmericanCountryAdenocarcinomaBaseActionable MutationBlindedCancer CareAmerican Society Of Clinical OncologyCancer DetectionCancer PatientAsiaChemotherapyClinicClinical DevelopmentBiopsyClinical PracticeClinical ResearchClinical Research SiteCollegeCancer CellDetection
Grant awards (5)
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2021 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2020 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$378,300
UH3 · FY2019 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2018 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2017 · CA